Background Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of idiopathic nephrotic syndrome (INS). We have evaluated the reliability of urinary neutrophil-gelatinaseassociated lipocalin (uNGAL), urinary alpha1-microglobulin (uα1M) and urinary N-acetyl-beta-D-glucosaminidase (uβNAG) as markers for differentiating MCD from FSGS. We have also evaluated whether these proteins are associated to INS relapses or to glomerular filtration rate (GFR).
Introduction
Idiopathic nephrotic syndrome (INS) remains the most frequent glomerular disease in children [1] with reported incidences of two to seven cases per 100,000 children [2] . It is caused by various entities that differ in their histopathological forms and clinical course [3] . Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the most common causes of INS, representing 80 and 20 % of the cases, respectively [3] . The pathogenesis of this disease is still unknown, and its clinical outcomes are determined by their histopathological diagnosis and responsiveness to steroid treatment. Steroid-sensitive INS (SSINS) is due to MCD in 80 % of cases and has a favorable long-term prognosis [3] , while steroid-resistant INS (SRINS) is mostly due to FSGS and is significantly associated with poor outcomes [4, 5] . INS can be associated with various proximal tubular dysfunctions, such as glycosuria, aminoaciduria and bicarbonate losses [6] . The results from a few studies have suggested that some low-molecular-weight proteins (LMWPs), such as urinary beta2-microglobulinuria (β2M) [6, 7] or urinary retinol binding protein (RBP) [6] , can predict steroid treatment responsiveness in INS. However, other studies have failed to prove a significant difference in the urinary excretion of β2M between SRINS and SSNS patients [8] . More recently, Bennett et al. [1] reported that urinary neutrophil gelatinase-associated lipocalin (uNGAL), which is a small protein belonging to the lipocalin superfamily, can be used to distinguish SSINS from SRINS. However, the literature regarding the use of this novel urinary marker in INS is limited to this one publication [1] , and to date no studies evaluating the role of uNGAL in MCD and FSGS patients have been published.
The primary aim of our study was to evaluate the role of three urinary LMWPs, namely, uNGAL, urinary alpha 1-microglobulin (uα1M) and urinary N-Acetyl-beta-Dglucosaminidase (uβNAG) in differentiating MCD from FSGS and to discuss the underlying pathophysiological mechanisms. A second aim was to evaluate whether these renal tubular proteinuria can be associated to INS relapses or to INS glomerular filtration rate (GFR) levels.
Materials and methods

Study population
This is a prospective cross-sectional study which received the approval of the local research ethics board; informed consent was obtained from all participants and/or their legal guardians. Forty-seven patients aged between 2 and 18 years, all diagnosed with INS, and 19 healthy age-matched controls, were included. Renal biopsy was performed in 44 patients with INS at the time of diagnosis for SRINS or steroid-dependent INS, or after three or more relapses in 1 year for frequent relapsers. Of the 47 patients with INS, three did not have a renal biopsy and were excluded from our study. The final study population (n=44) were divided into three groups, with group 1 (n=35, 35 biopsied) including patients with MCD, group 2 (n=9, 9 biopsied) including patients with FSGS and group 3 (n=19) including healthy control children. The median time with the interquartile range (IQR; 25th and 75th percentile) between initial diagnosis and time of inclusion in the study was 4 [2; 6] and 4 [3; 6] years for patients diagnosed with FSGS and MCD, respectively. Furthermore, children with INS were divided into two groups based on the urine specimen results independently of the histopathological diagnosis: (1) patients in remission (total n of patients in remission28: 21 MCD, 7 FSGS) and (2) patients in relapse (total n of patients in relapse16: 14 MCD, 2 FSGS). Remission was defined as a urinary protein over creatinine ratio of ≤20 g/mol or 0.2 g/g. Relapse was defined as a measurement of ≥2+ on urinary dipsticks for at least 3 consecutive days, as confirmed by a urine protein/creatinine ratio of >200 g/mol or 2 g/g. Urinary excretion of α1M, βNAG and NGAL were measured in all groups. The INS patients' demographic characteristics and treatment are summarized in Table 1 .
Analytical methods
Blood samples with lithium heparinate were processed immediately for plasma creatinine determination, and spot urine samples were analyzed immediately for creatinine, uNGAL, uα1M and uβNAG determination. Serum creatinine (SCreat) was measured on a Modular P system (Roche Diagnostics, Indianapolis, IN) using the kinetic colorimetric compensated Jaffe method from Roche Diagnostics. Inter-assay coefficients of variation obtained with the internal quality controls were 3.9 % at 46 μmol/l and 2.4 % at 108 μmol/l. Urine creatinine (uCreat) was determined using the same method but was calibrated in on a homemade aqueous creatinine solution of 15.1 mmol/l. Inter-assay CVs were 1.7 % at 7.2 mmol/l and 0.7 % at 12.8 mmol/l. uβNAG was measured with a colorimetric assay using sodium-3-cresolsulfonphthaleinyl-Nacetyl-β-D-glucosaminide as substrate (Roche Applied Science, Rotkreuz, Switzerland) adapted on a Modular P and calibrated with the uβNAG standard from Roche Applied Science. Inter-assay CVs were 1.2 % at 9 U/l and 0.9 % at 90 U/l. uNGAL was determined by a chemiluminescent microparticule immunoassay on an Architect i1000SR (Abbott Diagnostics, North Chicago, IL). During the entire study, inter-assay CVs determined on the three levels of internal quality controls were ≤2.2 % (respective means of controls: 21, 184 and 1,196 μg/l). uα1M was measured by immunonephelometry on a BN ProSpec analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY) with an inter-assay CV of 5.3 % at 37.7 mg/l.
GFR estimation methods
The estimated GFR (eGFR) was calculated using the revised Schwartz and the new Quadratic formulas as follows:
-Males:
In all formulas, height is in centimeters, SCreat is in milligrams per deciliter, eGFR is in milliliter per minute per 1.73 m 2
Histological evaluation of the renal biopsies
Renal tissue was obtained by percutaneous biopsy in 44 children diagnosed with INS. All specimens were fixed in Bouin's alcoholic solution, post-fixed in formalin and then embedded in Paraffin. Sections were cut at a thickness of 2-3 μm and stained routinely with hematoxylin and eosin, periodic acid-Schiff and periodic acid-silver-methenamine. All biopsy sections were examined by electron microscopy.
Statistical analysis
Collected data were analyzed using R software, version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria; www.R-project.org). Data were reported as medians with upper and lower quartiles for continuous parameters (IQR; 25th; 75th percentile), and categorical variables are expressed as percentages. The bilateral Fisher exact test was used for the comparison of nominal variables. For continuous variables, the difference was computed with the Mann-Whitney U test or the t test according to the number and normality of the data. Thus, for the comparisons between MCD and FSGS groups we used the Mann-Whitney U test, whereas the t test was used to compare the log-transformed uNGAL/uCreat ratio values between the control group and the pooled MCD and FSGS groups. Prognostic accuracies were assessed by receiver operating characteristic (ROC) curve analyses providing the area under the curve (AUC) and 95 % confidence intervals using a nonparametric approach as proposed by Delong [11] . Finally, correlation analysis of uα1M, uβNAG and uNGAL with the urinary protein excretion indexed to urinary creatinine was assessed using the Spearman rank correlation test, and linear regression analysis was performed using the logarithmic value of these (Fig. 1a) .
Correlation between uNGAL excretion and proteinuria level
The correlation between uNGAL indexed or not to the uCreat and the protein excretion related to uCreat in the whole study group with INS was close to 0 (Spearman correlation coefficient r −0.05 and −0.04 with p values of 0.75 and 0.81, respectively) ( Fig. 2a) and was also observed in MCD and FSGS patients. This latter observation demonstrated that the higher uNGAL values in FSGS, which enabled this group to be distinguished from the MCD group, were not related to a higher urinary protein/creatinine ratio. There was also no significant difference in median uNGAL indexed to the uCreat between patients in relapse versus those in remission (p=0.76) (Fig. 3a) . 
Correlation between uNGAL excretion and eGFR
For the each patient group, there was no significant correlation between uNGAL and the uNGAL indexed to the uCreat and the eGFR (p = 0.26 and 0.45, respectively, with the revised Schwartz formula, and p = 0.57 and 0.48, respectively, with the new Quadratic formula). Sub-analysis for the FSGS and MCD groups also showed no significant correlation between eGFR and uNGAL excretion. In addition, using a multivariate analysis in which eGFR was a controlling co-variate, we found that uNGAL distinguished between FSGS and MCD and that this difference was independent of GFR levels. These results indicated that the highest uNGAL levels obtained in our FSGS patients were not related to renal disease severity. (Fig. 1b) ; this value was not significant (p = 0.86). These results remained unchanged when uα1M was indexed to uCreat (AUC 0.60 [0.37; 0.82]; not significant p = 0.38).
Correlation between uα1M excretion and proteinuria level
For the whole group with INS, the correlation between the uα1M related to the uCreat and the protein excretion corrected for uCreat showed a positive and significant correlation coefficient (r=0.79, p<0.001) (Fig. 2b) . In addition, median uα1M related or not to the uCreat for patients in relapse was significantly higher than that for those children in remission (p=0.001) (Fig. 2c) , independently of the histopathological diagnosis.
Correlation between uα1M excretion and eGFR
The correlation between the uβNAG and the eGFR using the revised Schwartz and the new Quadratic formulas was poor and not significant (r=0.28 and 0.24, p=0.067 and 0.129, respectively), with no differences between the FSGS and MCD groups. 
Correlation between uβNAG excretion and proteinuria level
The correlation between uβNAG and the protein excretion corrected to uCreat was very low and not significant (r=0.12, p=0.38) (Fig. 2c) . On the other hand, there was no significant difference in median uβNAG indexed to the uCreat between patients in relapse versus those in remission (p=0.31) (Fig. 3c) .
Correlation between uβNAG excretion and eGFR
The correlation between the uβNAG and the eGFR using the revised Schwartz and the new Quadratic formulas was poor and not significant (r=0.25 and 0.24; p=0.106 and 0.120, respectively), again with no differences between the FSGS and MCD groups.
Discussion
Several tubular urinary markers have been studied in INS with conflicting results. Sesso et al. [6] showed that urinary RBP and β2M levels may be helpful biomarkers for distinguishing established SRINS from SSINS. Caliskan et al. [8] and Valles et al. [13] showed no difference in the urinary β2M excretion in children who are more likely to be responsive to steroid treatments. During the past few years, Fig. 3 Box plot for the median uNGAL to uCreat ratio (a), median uα1M to uCreat ratio (b) and median urinary N-Acetyl-beta- [14] and urinary cytokine panels [15] to identify whether any of these factors could distinguish SRINS from SSINS, but the results were nonconclusive. Bennett et al. [1] recently demonstrated that the ratio of uNGAL to urinary creatinine could be used to differentiate SSNS from SRNS; in addition, this new urinary biomarker was correlated with disease severity in SRNS.
Our study cohort comprised children with biopsy-proven established kidney disease. In this cohort, our results showed that using a cut-off value of 17 ng/mg, the uNGAL/uCreat ratio enabled MCD to be distinguished from FSGS with an AUC of 0.75 (p=0.01) and an optimized sensitivity of 0.77 and specificity of 0.78. This finding has important implications in clinical practice as we have demonstrated the role of uNGAL as a novel biomarker in children with INS, thereby confirming the findings of Bennett et al. [1] . We also found that uNGAL can readily distinguish between the two different histopathological glomerular diseases, independent of GFR or proteinuria levels.
The underlying pathophysiological mechanisms of uNGAL excretion/metabolism in INS are still unknown. Different hypotheses have been explored in previous investigations, such as an injured glomerular barrier, a possible adaptive tubular response to injury by NGAL inhibition of apoptosis or an abnormal cubulin-megalin transporter [16] .
Regarding urinary LMWP excretion in children with INS in remission or in relapse, we obtained discordant results. There was a significant increase in the median uα1M/uCreat ratio in children with relapse compared to those in remission. This increase in the uα1M/uCreat ratio was significant and positively related to the level of proteinuria (r = 0.79). However, the medians of the uNGAL/uCreat and uβNAG/uCreat ratios were not significantly different between children in remission and children in relapse. The observation of increasing uα1M concentration in relapsed INS compared to the remission state is consistent with the previously described hypothesis that proteinuria decreases the absorption of LWMP through competition for common transport mechanisms [17] [18] [19] [20] but it also does not exclude the association of proximal tubular injury related to interstitial fibrosis from the underlying disease [21] [22] [23] . This proximal tubular injury could also be secondary to tubular ischemia, as reported by Sesso et al. [6] . There is therefore a need for studies on the measurement of cellular tubular oxygenation during remissions and relapses to confirm or not the Sesso hypothesis.
In brief, mechanisms of urinary excretion of LWMP in the condition of relapsed INS are still not well established and may be secondary to several tubular pathophysiological processes. A delicate and complicated interplay, as yet not completely resolved, between uNGAL, the glomerular filtration process; proximal tubular reabsorption and distal tubular secretion might explain the lack of difference between uNGAL concentration in children with INS in relapse and in remission.
There are a number of limitations to this study. First, the majority of children with FSGS were already on calcineurin inhibitor (CNI) treatment at the date of inclusion. Several studies showed contrasting results regarding the impact of CNI on uNGAL excretion in children with INS [1, 24] . The number of children included was fairly small, especially in the FSGS group, and therefore, the impact of CNI could not be evaluated in our study group. Secondly, although we found a uNGAL cut-off with good sensitivity and specificity, additional larger studies are needed to validate this new urinary cut-off as a potential alternative marker that could replace renal biopsy. Finally, given the fact that all our FSGS patients had histological lesions not otherwise specified, we could not assess the role of FSGS subtypes on uNGAL excretion.
To our knowledge, this study is the first to demonstrate that uNGAL can distinguish children with biopsy-proven MCD from those with FSGS In addition, we provide a urinary NGAL to creatinine ratio cut-off point that can be helpful in clinical practice to differentiate these two histopathological diagnoses.
